Genomenon and Amicus Team Up to Enhance Awareness and Diagnosis of Fabry Disease Genomenon collaborates with Amicus Therapeutics to improve the awareness, diagnosis, and research of Fabry disease by expanding genetic variant data.

Genomenon and Amicus Team Up to Enhance Awareness and Diagnosis of Fabry Disease #United_States #Ann_Arbor #Fabry_disease #Genomenon #Amicus_Therapeutics

BioMarin Pharmaceutical Inc. Reports Significant Growth in Revenues and Plans for 2026 Acquisitions BioMarin Pharmaceutical Inc. showcased an impressive revenue growth for 2025 and announced future acquisition plans that could elevate its market position significantly.

BioMarin Pharmaceutical Inc. Reports Significant Growth in Revenues and Plans for 2026 Acquisitions #USA #San_Rafael #BioMarin #VOXZOGO #Amicus_Therapeutics

BioMarin Unveils Plans for $850 Million Senior Note Offering and $2 Billion Secured Loan BioMarin Pharmaceutical Inc. has announced a proposed $850 million offering of senior notes and a $2 billion secured term loan as part of its acquisition strategy.

BioMarin Unveils Plans for $850 Million Senior Note Offering and $2 Billion Secured Loan #United_States #Senior_Notes #San_Rafael #BioMarin #Amicus_Therapeutics

M&A Class Action Firm Investigates Notable Corporate Mergers: EKSO, FOLD, CWAN, and JHG The M&A Class Action Firm, led by attorney Juan Monteverde, is probing potential shareholder claims related to significant mergers involving EKSO Bionics, Amicus Therapeutics, Clearwater Analytics, and Janus Henderson.

M&A Class Action Firm Investigates Notable Corporate Mergers: EKSO, FOLD, CWAN, and JHG #USA #New_York #Janus_Henderson #Amicus_Therapeutics #EKSO_Bionics

Halper Sadeh LLC Urges Shareholders of KPLT, FOLD, and DHIL to Assert Their Rights Halper Sadeh LLC is investigating potential shareholder rights violations by KPLT, FOLD, and DHIL. Shareholders are encouraged to explore their options.

Halper Sadeh LLC Urges Shareholders of KPLT, FOLD, and DHIL to Assert Their Rights #New_York #US #Diamond_Hill #Amicus_Therapeutics #Katapult_Holdings

Investigation Into Amicus Therapeutics' Shareholder Deal Raises Concerns The Ademi Firm is probing potential violations by Amicus Therapeutics in a significant deal impacting its public shareholders, focusing on fiduciary duties.

Investigation Into Amicus Therapeutics' Shareholder Deal Raises Concerns #USA #Milwaukee #Shareholder_Rights #Ademi_Firm #Amicus_Therapeutics

Kaskela Law LLC Initiates Investigation into Amicus Therapeutics Over Shareholder Concerns Kaskela Law LLC is investigating Amicus Therapeutics for potential securities violations, urging shareholders to engage for legal insights and options.

Kaskela Law LLC Initiates Investigation into Amicus Therapeutics Over Shareholder Concerns #United_States #Philadelphia #Shareholder_Rights #Kaskela_Law #Amicus_Therapeutics